FDA Panel Unanimously Endorses Lecanemab for Alzheimer's
FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug's clinical benefit for patients with Alzheimer's disease.
Stay updated with breaking news from Robertc Alexander. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drug's clinical benefit for patients with Alzheimer's disease.
Arrests in the Cayuga County area reported by Auburn Police Department, New York State Police and the Cayuga County Sheriff's Office.
FDA seems poised to approve a new drug for ALS, but does it work?
In March, experts who advise the FDA questioned the efficacy of an experimental new drug for ALS. In September, they voted to approve it anyway.
In March, experts who advise the FDA questioned the efficacy of an experimental new drug for ALS. In September, they voted to approve it anyway.